FDA Greenlights New First-Line Regimen in Bladder Cancer

(MedPage Today) -- The FDA gave accelerated approval to enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) as first-line treatment for certain patients with locally advanced or metastatic urothelial cancer, the agency announced on Monday...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news